Investor Presentaiton
Excellent Performance of HANQUYOU
Higher sales per capita
than domestic peers
Sales Per Capita¹
(2023)
>5M RMB
The only Trastuzumab
with two specifications
2 specifications were
customized to address HER2+
breast cancer patients medical
needs in China
Solved the issue of residual
liquid storage, improving drug
use safety and honing product
differentiation advantage
60
150
mg mg
Strengthen product
differentiation for
competitive advantages
In 2023, the competition has
become complicated when
other local trastuzumab
products had been marketed
With advanced planning and
preparation, HANQUYOU
have enhanced the market's
recognition of the product
advantages on international
quality and two specifications
Bold expansion into
broad market
Trastuzumab has wide
application and its sales in the
broad market (outside the
Top1,000 hospitals) have
increased rapidly, resulting to
fast-growing market share in
China
HANQUYOU has expanded
the coverage with marketing
activities in lower tier areas to
capture potential of broad
market
* Sales per capita = Product sales / # of salesforce
2 Henlius
11
O 2024 Henlius.View entire presentation